General Information of Drug (ID: DM4Z9QI)

Drug Name
Olokizumab Drug Info
Indication
Disease Entry ICD 11 Status REF
Rheumatoid arthritis FA20 Phase 3 [1]
Coronavirus Disease 2019 (COVID-19) 1D6Y Phase 2/3 [2]
Cross-matching ID
TTD Drug ID
DM4Z9QI

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Interleukin-6 (IL6) TTT1V78 IL6_HUMAN Modulator [3]
HUMAN interleukin 6 (IL6) TTJH4Y5 IL6_HUMAN Inhibitor [4]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Interleukin-6 (IL6) DTT IL6 5.133 5.921 4.797 7.627
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Rheumatoid arthritis
ICD Disease Classification FA20
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Interleukin-6 (IL6) DTT IL6 8.08E-01 -0.77 -1.15
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 ClinicalTrials.gov (NCT04380519) Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19). U.S. National Institutes of Health.
3 Efficacy and safety of olokizumab in patients with rheumatoid arthritis with an inadequate response to TNF inhibitor therapy: outcomes of a randomised Phase IIb study. Ann Rheum Dis. 2014 September; 73(9): 1607-1615.
4 Discovery and characterization of olokizumab: a humanized antibody targeting interleukin-6 and neutralizing gp130-signaling. MAbs. 2014 May-Jun;6(3):774-82.